Brii Biosciences Closes US$155M Series C Financing

Brii Biosciences, a Durham, NC- and Beijing, China-based multi-national company developing innovative therapies for diseases including infectious diseases, liver diseases, and CNS diseases, closed a Series C financing of US$155m.

The round was led by Invesco Developing Markets Fund, with additional funding provided by GIC and another global leading investment management organization, followed by Lake Bleu Capital and an Asia-based investment organization, as well as three current investors.

The company intends to use the funds to advance its broad infectious diseases pipeline as well as its CNS program.

Led by Zhi Hong, Ph.D., CEO, Brii Bio is currently conducting clinical studies in multiple infectious diseases, and is preparing to enter clinical-stage research in diseases of the central nervous system. The company’s programs include:

  • HBV: Initiation of a phase 2 study of BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) in patients who are chronically infected with HBV is planned for March 2021, and will be the subject of a separate announcement.
  • COVID-19 antibody therapies: BRII-196 and BRII-198, non-competing SARS-CoV-2 neutralizing antibodies are part of the Phase 2/3 studies under ACTIV-2 master protocols, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH).
  • Multi-drug resistant Gram-negative bacterial infections: BRII-636 (OMNIvanceTM), BRII-672 (ORAvanceTM) and BRII-693 (QPX-9003) are potent antibiotics against WHO-designated critical pathogens for the treatment of carbapenemase producing Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii.
  • New HIV treatment options – Once Weekly Single Tablet Regimen (QW STR): phase 1 clinical study for BRII-778 has started and a U.S IND for BRII-732 was submitted in March. The company will investigate the potential of prolonged dosing interval for treatment of people who live with HIV.
  • Novel treatment for central nervous system (CNS) disease: The phase 1 clinical trials for BRII-296 will begin shortly under a U.S. IND.